When does Qulipta (atogepant) lose exclusivity or patent protection?
Qulipta’s exact “expiry date” depends on which legal protection you mean. For prescription drugs, exclusivity/patent timelines can include multiple layers (for example, composition-of-matter patents, formulation/process patents, and regulatory exclusivity such as FDA marketing exclusivity). Public sources that track these dates typically break them out by patent and filing family rather than giving one single calendar date.
DrugPatentWatch tracks patent and exclusivity-related information for branded drugs, including atogepant (Qulipta), and is a practical place to check the specific end dates by patent family: DrugPatentWatch – Qulipta (atogepant).
Is there one “FDA exclusivity expiry” date for Qulipta?
Usually not. The date most people mean as “expiry” is often a mix of:
- Patent expiry (when other manufacturers may be able to file an Abbreviated New Drug Application or related filings, depending on legal status), and
- Regulatory exclusivity (which can delay certain approvals even if patents have ended or even if filings are made).
To determine the correct date for “generic availability” versus “patent expiry,” you have to map the specific patents/exclusivities listed for atogepant on an up-to-date tracker.
How can I find the specific Qulipta end date that matters for generics?
Search for the most relevant item on a tracker like DrugPatentWatch and look for:
- “Last patent expiry” or similar phrasing tied to the relevant patent family, and
- Any “regulatory exclusivity” entries, if available for atogepant.
Because these dates can change with legal events (for example, patent challenges, settlements, or additional patents), the most accurate approach is to use an up-to-date patent database entry rather than relying on a single year.
What if you meant “when will Qulipta go generic”?
“Go generic” typically tracks the earlier of the legal barriers that block approval of a generic (and can involve both patents and exclusivity). That timing can differ from the last patent expiry date depending on the patent landscape and any pending litigation.
For the best “generic timing” estimate, use the patent-and-exclusivity timeline shown for atogepant on DrugPatentWatch: DrugPatentWatch – Qulipta (atogepant).
Sources
- DrugPatentWatch – Qulipta (atogepant)